Provectus Pharma meets FDA over metastatic melanoma trial
The meeting was held particularity to address topics central to definition of the applicable patient population and primary endpoint for the Phase 3 randomized controlled trial (RCT) of
China-based IMPACT Therapeutics and Pharmanovia have entered an exclusive licensing deal worth up to €423.5m ($488.3m), giving Pharmanovia rights to manufacture, develop, and commercialise senaparib in 66 countries.